C14 faces a challenging road ahead. It's worth considering that big pharmaceutical companies might prefer the steady revenue stream from lifetime ART treatments over wanting a cure. The financial risks and costs of large-scale cure studies could deter them and their ever-increasing ART revenue stream. Only benevolent BIT investors and/or those with the disease want a cure not necessarily the people or companies that can make it happen.
For now, C14 appears to be our best hope in raising awareness / finding a suitable investor.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.654M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $210 | 104.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 64 | 38848316 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 18281126 | 25 |
View Market Depth
| Last trade - 12.28pm 27/06/2025 (20 minute delay) ? |
| BIT (ASX) Chart |